ExteNET

Design, population and eligibility

Treatment and comparator

Neratinib 240 mg orally once daily for 12 months versus matching placebo. Participants had completed chemotherapy and trastuzumab-based primary therapy. The original trial did not use protocol-directed antidiarrhoeal prophylaxis.

Primary and secondary endpoints

Prespecified 5-year analysis endpoint: invasive disease-free survival (iDFS) by intention-to-treat. Other outcomes included distant and locoregional recurrence, OS and safety.

Key efficacy results

At median 5.2-year follow-up, 116 iDFS events occurred with neratinib versus 163 with placebo; HR 0.73 (95% CI 0.57–0.92; p=0.0083). Five-year iDFS was 90.2% (95% CI 88.3–91.8) versus 87.7% (95% CI 85.7–89.4).

In the exploratory HR-positive subgroup starting neratinib within one year of trastuzumab, the absolute iDFS benefit was approximately 5.1 percentage points; subgroup selection and timing should be interpreted in light of the analysis plan.

Source-reported outcome visualization

Five-year invasive disease-free survival.

Absolute difference 2.5 percentage points in the overall intention-to-treat population.

Absolute effect

Absolute 5-year iDFS gain: 2.5 percentage points. Approximate NNT 40 for one additional patient alive without an invasive disease-free survival event at 5 years. This is an iDFS endpoint-specific NNT, not an OS NNT.

Trial-specific toxicity and treatment burden

Without prophylaxis, grade 3 diarrhoea occurred in 40% and grade 4 diarrhoea in <1% with neratinib (grade 3 diarrhoea 2% with placebo). Grade 3 vomiting occurred in 3% versus <1%; grade 3 nausea in 2% versus <1%. Treatment-emergent serious adverse events occurred in 7% versus 6%. Diarrhoea was a major cause of dose interruption, reduction and discontinuation; FDA review reports 16.8% discontinuation due to diarrhoea.

The CONTROL study later showed that prophylaxis and dose-escalation strategies can mitigate diarrhoea, but these were not the ExteNET protocol.

Quality of life and patient-reported outcomes

FACT-B and other patient-reported analyses did not show a sustained clinically meaningful global QoL decrement across most follow-up points, although early gastrointestinal symptoms can affect daily functioning. The treatment burden is one additional year of oral therapy and proactive diarrhoea management.

Subgroups and applicability

The largest apparent benefit was in HR-positive patients who started neratinib within one year after trastuzumab. This is a clinically relevant but subgroup-specific finding; the study was not designed to establish benefit after contemporary pertuzumab or T-DM1.

Current-practice context · reviewed 2 November 2026

Neratinib may be considered for selected high-risk HR-positive/HER2-positive patients after trastuzumab-based therapy, particularly where residual risk remains and treatment can begin within one year. Its role after modern pertuzumab and T-DM1 sequences is less directly evidenced; diarrhoea prophylaxis/dose escalation is essential.

Limitations and critical interpretation

The absolute overall-population iDFS benefit is modest. The trial predates current HER2-directed sequencing, had substantial diarrhoea without prophylaxis and did not establish an OS benefit at the 5-year report. Subgroup findings should not be generalized to all HER2-positive patients.

Bottom line: ExteNET demonstrates a statistically significant but modest 5-year iDFS improvement with extended neratinib, with the clearest signal in HR-positive disease started soon after trastuzumab. The benefit must be balanced against substantial diarrhoea and limited evidence after modern HER2 therapy.

Primary sources and follow-up publications

1. ExteNET 5-year analysis, Lancet Oncology 2017
2. ExteNET original report, Lancet Oncology 2016
3. Neratinib diarrhoea and QoL analysis
4. ExteNET registry

All outcome values above are transcribed from the linked trial reports or their prespecified follow-up publications. Unreported values are not imputed. No NNT is derived from median survival.